Some of our top FTSE 100 companies have had a tough year in 2014, but thats left us with some tempting recovery candidates for 2015. Here are three you might care to ponder while recovering from your own festive activities:
Ive lost count of the number of times Ive heard (or even said myself) that Tesco (LSE: TSCO) surely cant fall any further and then it does!
The latest bad news was a surprise profit warning on 9 December, which slashed expected full-year trading profit to 1.4bn less than half of 2013s figure! Some are even expecting the already-pared dividend to be cut further, but Id be surprised if that happens.
When we get TescosChristmastrading update due in early January I wouldnt be too shockedto hear further bad news, and that could knock the share price further. But even with reduced forecasts, 2015 could well prove to be the bottom in terms of both profitability and share price.
The big problem for BG Group (LSE: BG) is the plummeting price of oil although Brent Crude has ticked up sincedipping below $60, and the BGshare price has come back a little in response.
Oil prices this low are not sustainable over the long term, as the cost of production for many companies (and entire countries, in fact) is just too highto keep volumes up. So well surely see a recovery in oil prices in 2015 and BG, with its 570,000 barrels per day plus its status asthe largest supplier of liquified natural gasto the United States, should benefit.
Forecast dividend yields are modest, but they should be aroundthrice covered.
GlaxoSmithKline (LSE: GSK) used to be though of as the UKs number one in the pharmaceuticals business with AstraZeneca placed second but what a difference a few years plus Pascal Soriot can make! Astra has leapfrogged Glaxo in the race to rebuild developmentpipelines after the loss of patent protection on a number of key drugs.
But with Glaxosshare price down around 15% in the past 12 months and 2015 expected to be the year its fall in earnings per share is arrested, we could be looking at turnaround time for the shares too.
Dividends are expected to be maintainedand would yield 5.9% this year and next if forecasts come good they wouldnt quite be covered by earnings, but Glaxo has the cash to make those payments in the short term.
Looking for recovering blue-chipstocks like these three could give yourmillionaire aspirationsa boostin 2015.
Ifyou have an ambitious target, the Motley Fool’s 10 Steps To Making A Million In The Market shows you how a simple strategy followed over the long term can turn modest regular investing into a very significant cash pile. And it’s FREE.
But hurry, as it won’t be available for ever. Just click here for your personal copy today.
Get FREE Issues of The Motley Fool Collective
Get straightforward advice on whats really happening with the stock markets, direct to your inbox. Help yourself with our FREE email newsletter designed to help you protect and grow your portfolio wealth.